RAS-Partner Program

The RAS-Partner Program is a discovery-stage drug development initiative by Quanta Therapeutics focused on treating RAS-driven tumors. The program utilizes small molecules discovered via a proprietary Second Harmonic Generation (SHG) platform to achieve direct allosteric modulation of signaling complexes within the Mitogen-Activated Protein Kinase (MAPK) pathway. These candidates are designed to be orally bioavailable and CNS-penetrant, potentially addressing both primary tumors and brain metastases. The molecules are being developed for use as both monotherapies and synthetic lethal combination partners across a broad spectrum of RAS-mutant cancers, aiming to overcome the limitations of traditional RAS-targeting therapies by focusing on the protein-protein interactions within the signaling complexes.

Other names

MAPK pathway signaling complexes program